Top Anti Cancer Imported Medicine Drugs in India - Pharma Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Jemperli (Dostarlimab-gxly) Medicine in India

Jemperli (Dostarlimab-gxly)

Medicine name : Jemperli

Generic name : Dostarlimab-gxly

Manufactured By : GSK

Indications : Treatment of adults with Stage II or III locally advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) rectal cancer.

Medicine Description : An immunotherapy for adults with Stage II or III locally advanced MSI-H or dMMR rectal cancer. Jemperli (Dostarlimab-gxly) blocks the PD-1 protein, helping the immune system recognise and attack cancer cells.

Product Introduction

Jemperli (Dostarlimab-gxly) is an immunotherapy medicine used to treat adults with Stage II or Stage III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This indication is approved under the FDA accelerated approval pathway and requires confirmation of the tumour's biomarker status using an FDA-authorised test.

Jemperli belongs to a class of medicines called programmed death receptor-1 (PD-1) blockers. It works by blocking the PD-1 pathway, helping the body's immune system recognise and attack cancer cells. For this rectal cancer indication, it is administered as an intravenous infusion by a qualified healthcare professional, following the prescribed treatment schedule.

Common side effects may include fatigue, skin rash, diarrhoea and itching. Serious side effects can include immune-related inflammation affecting organs such as the lungs, liver, kidneys, intestines and thyroid. Regular medical monitoring is essential, and patients should promptly report unusual or worsening symptoms.

Uses Of Jemperli (Dostarlimab-gxly)

Treatment of MSI-H/dMMR Locally Advanced Rectal Cancer

Benefits Of Jemperli

Used alone to treat adults with Stage II or Stage III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), confirmed by an FDA-authorised test. This indication is approved under the FDA accelerated approval pathway.

Side Effects Of Jemperli (Dostarlimab-gxly)

Some patients may experience side effects during treatment with Jemperli (Dostarlimab-gxly). The severity can vary depending on individual health and treatment response.

Common Side Effects of Jemperli (Dostarlimab-gxly)

  • Fatigue
  • Skin rash
  • Diarrhoea
  • Itching
  • Nausea
  • Constipation
  • Headache
  • Joint pain
  • Fever
  • Decreased appetite
How To Use Jemperli

Jemperli is administered as an intravenous infusion by a qualified healthcare professional over approximately 30 minutes. For adults with Stage II/III MSI-H or dMMR locally advanced rectal cancer, the recommended dose is 500 mg once every 3 weeks for 9 cycles. The treatment schedule and continuation are determined by the treating oncologist.

How Jemperli (Dostarlimab-gxly) Works

Jemperli is a programmed death receptor-1 (PD-1) inhibitor. It blocks the interaction of PD-1 with its ligands PD-L1 and PD-L2, helping restore T-cell activity and allowing the immune system to recognise and attack cancer cells.

Storage Conditions
  • Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F).
  • Keep vials in their original carton to protect them from light.
  • Do not freeze or shake the vials.
  • After dilution, use the prepared infusion solution within 6 hours at room temperature or 24 hours under refrigeration (2°C to 8°C). Allow refrigerated solution to reach room temperature before administration.
Safety Advice

AlcoholAlcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment. Avoid excessive alcohol, especially if you experience fatigue, nausea or other side effects.

PregnancyPregnancy CONSULT YOUR DOCTOR

Jemperli may cause harm to an unborn baby. Confirm pregnancy status before treatment and use effective contraception during treatment and for 4 months after the last dose.

BreastfeedingBreastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment or for 4 months after the last dose, due to the potential risk of serious adverse reactions in the infant.

DrivingDriving CONSULT YOUR DOCTOR

Jemperli may affect your ability to concentrate if you experience fatigue, dizziness or other side effects. Avoid driving if your alertness is affected.

KidneyKidney CAUTION

Inform your doctor about existing kidney problems. Regular kidney-function monitoring is important because immune-mediated kidney inflammation may occur.

LiverLiver CAUTION

Inform your doctor about existing liver disease. Regular liver-function tests are important because Jemperli may cause immune-mediated hepatitis.

Quick Tips
  • Receive Jemperli only through intravenous infusion under medical supervision.
  • Follow the prescribed treatment schedule and attend all appointments.
  • Inform your doctor about existing medical conditions and all medicines you take.
  • Report diarrhoea, persistent cough, breathing difficulties or unusual symptoms promptly.
  • Attend regular blood tests and follow-up examinations to monitor treatment response and side effects.
  • Read More About - Jemperli (Dostarlimab-gxly) from Pharma Five.
About Pharma Five

Pharma Five assists patients seeking Jemperli (Dostarlimab-gxly) by facilitating the import of limited quantities for personal medical use, subject to applicable regulations. Depending on the requirements, Form 12A, a valid prescription from a Registered Medical Practitioner (RMP) and other supporting documents may be required.

With more than 20 years of pharmaceutical industry experience, Pharma Five offers specialised medicine consultancy and import assistance for patients requiring Jemperli (Dostarlimab-gxly). The team provides guidance on documentation and helps patients navigate the applicable medicine import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

References
  1. https://go.drugbank.com/drugs/DB15627
  2. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer
  3. https://dailymed-beta.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=095eab9f-545a-4f12-bfb7-19477fb901a5
  4. https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-approved-in-us-as-first-and-only-immunotherapy-for-adults-with-msi-hdmmr-locally-advanced-rectal-cancer
Faq

General Question

Jemperli (Dostarlimab-gxly) is an immunotherapy medicine used to treat certain cancers. It is indicated for adults with Stage II or Stage III locally advanced MSI-H or dMMR rectal cancer under the FDA accelerated approval pathway.

Jemperli blocks the PD-1 pathway, preventing cancer cells from suppressing immune activity. This helps the body's T cells recognise and attack cancer cells.

Jemperli is prescribed for eligible adults with certain cancers, including Stage II or Stage III locally advanced MSI-H or dMMR rectal cancer. A specialist confirms the diagnosis and biomarker status before recommending treatment.

Jemperli is administered through an intravenous infusion by a qualified healthcare professional, usually over approximately 30 minutes. The dose and treatment schedule depend on the cancer type and prescribed regimen.

Common side effects may include fatigue, skin rash, diarrhoea, itching, nausea, constipation, headache, joint pain, fever and decreased appetite.

Yes. Jemperli can cause serious immune-related reactions affecting the lungs, liver, kidneys, intestines, thyroid and other organs. Severe skin reactions and infusion-related reactions may also occur. Report unusual or worsening symptoms promptly.

Treatment duration depends on the cancer type, treatment response and side effects. For the Stage II or III locally advanced MSI-H or dMMR rectal cancer regimen, the prescribed schedule may include 500 mg every three weeks for nine cycles. Your oncologist determines the appropriate duration.

Consult your doctor before consuming alcohol during treatment. Discuss alcohol use with your healthcare team, particularly if you experience fatigue, nausea or other treatment-related symptoms.

Jemperli may cause harm to an unborn baby. Women who can become pregnant should use effective contraception during treatment and for 4 months after the last dose.

Inform your doctor about all prescription medicines, over-the-counter products, vitamins and supplements you use. Your healthcare team should also know about any other cancer treatments or immune-modulating medicines.

If you miss a scheduled infusion, contact your healthcare provider as soon as possible to arrange another appointment. Do not attempt to compensate for the missed dose yourself.

Jemperli is administered directly into a vein, so food does not affect its administration. Follow your doctor's dietary recommendations during treatment.

Attend all scheduled appointments and blood tests. Inform your doctor about existing medical conditions and report persistent diarrhoea, breathing difficulties, severe rash, yellowing of the skin or other unusual symptoms promptly.

Store unopened Jemperli vials in a refrigerator at 2°C to 8°C (36°F to 46°F), in the original carton to protect them from light. Do not freeze or shake the vials.

Pharma Five provides medicine consultancy and import facilitation for patients seeking Jemperli (Dostarlimab-gxly). Assistance with personal-use medicine imports is subject to applicable regulations, prescriptions and supporting documentation. Pharma Five assists in its procurement.

Timely Service
Doorstep Delivery
Hassle-Free Process
100% Genuine Sources